Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Regulations to be eased to create India’s Big Four
- Fifty Airports, Five Years: All About Government's Plan To Take Air Connectivity To India's Smaller Cities
- No time to cook? This AI-powered ‘up-liance’ will prepare your hearty meals
- Expert Views: India Unveils Budget In Wake Of COVID-19 Slump, Proposes Doubling Healthcare Spending
